Navigation Links
Tarix Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Study of TXA127 Following Autologous Peripheral Blood Stem Cell Transplant
Date:2/23/2011

CAMBRIDGE, Mass., Feb. 23, 2011 /PRNewswire/ -- Tarix Pharmaceuticals (www.tarixpharma.com) today announced enrollment of the first patient in a Phase 2 clinical study of TXA127, a pharmaceutical grade formulation of a naturally occurring peptide known to stimulate early hematopoietic precursor cells in the bone marrow.  The study is currently enrolling patients undergoing autologous peripheral blood stem cell transplant to evaluate the safety and efficacy of TXA127 in accelerating engraftment following transplant.

Following a stem cell transplant, it can typically take several weeks for the stem cells to repopulate the patient's blood with platelets and other mature blood cells. During this time the patient is at increased risk of serious infection and bleeding. There are currently no drugs available that speed up the engraftment process.

"TXA127 has the potential to reduce the time it takes for blood cell counts to return to safe levels following stem cell transplant, which may accelerate the recovery process and reduce some of the health risks associated with stem cell transplant," stated Rick Franklin, CEO of Tarix Pharmaceuticals. "TXA127 is unique because it directly stimulates transplanted stem cells to replenish circulating platelets, white blood cells, and red blood cells."

TXA127 was granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) as a treatment to enhance engraftment in patients receiving a stem cell transplant. TXA127 has also received Orphan Drug designation for the treatment of Myelodysplastic Syndrome (MDS).

About the Phase 2 Program

The double-blind, placebo-controlled multi-center Phase 2 study will evaluate the safety and efficacy of TXA127 in the acceleration of engraftment following autologous peripheral blood stem cell transplant in patients with Hodgkin or non-Hodgkin lymphomas or multiple myeloma undergoing limited reinfusion of CD34+ cells. The study is expected to enroll a total of 74 patients at eight leading U.S. medical centers. For more information, please visit http://clinicaltrials.gov/ct2/show/NCT01121120?term=tarix&rank=2.

TXA127 will also be evaluated in two clinical trials in cord blood transplantation. One conducted at M D Anderson will involve adult patients, while the other at Duke University, will enroll pediatric patients.

About Tarix Pharmaceuticals

Tarix Pharmaceuticals is a clinical stage biopharmaceutical company developing peptide drugs to address significant unmet medical needs. The Company's lead product, TXA127, is a pharmaceutical formulation of the naturally occurring peptide, Angiotensin (1-7). TXA127 is currently in a Phase II clinical trial for the treatment and prevention of thrombocytopenia (reduced platelet count) associated with cancer chemotherapy, and a Phase II trial for peripheral blood stem cell engraftment. Tarix is preparing additional clinical trials with TXA127 in acute respiratory distress syndrome (ARDS), cord blood stem cell engraftment, and myelodysplastic syndrome (MDS). TXA127 is also being developed, under grants from the US government, as a treatment for radiation exposure.

Tarix's second product, PanCyte, is a synthetic, long-acting analogue of Angiotensin (1-7). PanCyte is in pre-clinical development focused on chemotherapy-induced thrombocytopenia and neutropenia, as well as combination treatment with low dose erythropoietin in chemotherapy-induced anemia.


'/>"/>
SOURCE Tarix Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Components of Extraneous Virus Detected in Rotarix Vaccine; No Known Safety Risk
2. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
3. New Data Published in The Lancet Show GSKs ROTARIX(R) Offers Protection Against the Most Common Circulating Rotavirus Types
4. New Data Show That GlaxoSmithKlines Rotarix(R) Could Be Given With Other Routine Infant Vaccines in the U.S.
5. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
6. Onyx Pharmaceuticals Reports Full Year and Fourth Quarter 2010 Financial Results
7. Avanir Pharmaceuticals to Present at Three Conferences in March
8. MAP Pharmaceuticals to Present at Upcoming Investor Conferences
9. Isis Pharmaceuticals Reports That Its Selective CRP Inhibitor Demonstrated Activity in a Phase 1 Study
10. Isis Pharmaceuticals to Present at the 2011 Citi Global Healthcare Conference
11. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Israel , March 27, 2017 ... THXBY), a specialty clinical-stage pharmaceutical company specializing in the development ... its public offering in the United ... (ADSs), each ADS representing 40 ordinary shares of ... ADS. In addition, Therapix has granted the underwriters ...
(Date:3/27/2017)... STUTTGART, Germany , March 27, 2017 /PRNewswire/ ... provide over 7,000 attendees and more than 600 ... learn, and discover opportunities and solutions that will ... - 6 April 2017 at the Messe Stuttgart, ... is the preeminent medical technology platform showcasing the ...
(Date:3/27/2017)... FinancialBuzz.com News Commentary  ... Based on New Frontier Data,s sales forecasts in 2017, estimates ... generate $655 million in taxes on retail sales. Out of this ... Washington State,s 37% cannabis retail tax rate. ... that are applied on all retail sales. By 2020, tax revenues ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... Alert Sentry Group LLC., a ... Personal Emergency Response Systems), the iSAFE and the iSAFE Plus. These iSAFE products are ... of their kind, the iSAFE and iSAFE Plus offer direct GPS Location and two-way ...
(Date:3/28/2017)... ... March 28, 2017 , ... Calibration, ... to ensuring high-quality results and maintaining GMP and USP compliance. In a new ... accordance with GMP requirements " these requirements are explained. The challenge is ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... measurement of corrosive ions found in power plant water and steam. , Chlorides ... as turbines and boilers, leading to extensive maintenance and unplanned shutdowns. Monitoring these ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... offered by the American Association of Integrative Medicine and available for application on ... at the AutismOne 2017 Conference in Colorado Springs. , Ed Arranga, president of ...
(Date:3/28/2017)... ... March 28, 2017 , ... Silicon Valley Hair Institute, the San Francisco ... blog post about women’s hair loss. Although hair transplant procedures can be seen as ... Menopause or genetics can be two reasons a woman may see her hair thinning. ...
Breaking Medicine News(10 mins):